Beta Bionics CFO sells 4,413 shares under 10b5-1 at $17.01 avg

Rhea-AI Filing Summary

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions dated 08/22/2025. He exercised an employee stock option with a $5.10 exercise price to acquire 4,413 shares and immediately sold those 4,413 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $17.014 per share (range $17.00–$17.12). After these transactions his beneficial ownership declined from 49,916 shares to 45,503 shares. The option vests in 48 equal monthly installments beginning 09/14/2023 and expires 09/13/2033.

Positive

• Transaction executed under a Rule 10b5-1 plan, reducing regulatory risk and signalling preplanned liquidity
• Option exercised in-the-money (exercise $5.10 versus sale weighted avg $17.014), indicating value capture for the reporting person
• Clear disclosure of sale price range and weighted average, enhancing transparency

Negative

• Beneficial ownership decreased from 49,916 to 45,503 shares, reducing insider stake
• Immediate sale of exercised shares may be viewed negatively by some investors seeking insider accumulation

Insights

Securities Analyst

TL;DR: Routine option exercise followed by structured sale under a 10b5-1 plan; ownership modestly reduced, proceeds realized near market.

The reporting CFO exercised an in-the-money option (exercise $5.10) and sold the resulting 4,413 shares under a pre-established Rule 10b5-1 plan at a weighted average of $17.014, realizing gross consideration roughly equal to $75,000 (before fees/taxes). This is a common liquidity event for insiders and is executed under an affirmative defense plan, reducing reported beneficial ownership by ~8.8% of prior holdings (49,916 to 45,503). No additional compensatory or irregular transactions are disclosed.

Corporate Governance Expert

TL;DR: Transaction appears compliant with governance best practices due to 10b5-1 plan use and clear disclosure.

Use of a documented Rule 10b5-1 plan (adopted May 15, 2025) provides an affirmative defense against insider trading allegations, and the Form 4 discloses price range and weighted average sale price as required. The immediate sale of exercised shares is consistent with common executive liquidity management. The filing clearly states vesting schedule and option expiry, supporting transparency for shareholders and regulators.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		M		4,413	A	$5.1	49,916	D
Common Stock	08/22/2025		S(1)		4,413	D	$17.014(2)	45,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.1	08/22/2025		M			4,413	(3)	09/13/2033	Common Stock	4,413	$0	99,695	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

2. The weighted average sale price for the transaction reported was $17.0140 and the range of prices were between $17.00 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

	/s/ Stephen Feider	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Beta Bionics (BBNX) insider Stephen Feider report on Form 4?

He exercised an employee option for 4,413 shares at $5.10 and sold those 4,413 shares on 08/22/2025 under a Rule 10b5-1 plan at a weighted average price of $17.014.

How did Stephen Feider's ownership change after the transactions?

His beneficial ownership decreased from 49,916 shares to 45,503 shares following the exercise and sale.

Was the sale preplanned or discretionary?

The sale was executed pursuant to a Rule 10b5-1 plan adopted on May 15, 2025, indicating a preplanned sale program.

What was the sale price range and weighted average for the shares sold?

The sale price range was $17.00 to $17.12 with a weighted average sale price of $17.0140 per share.

What are the key terms of the exercised option?

The option has a $5.10 exercise price, vests in 48 equal monthly installments measured from 09/14/2023, and expires on 09/13/2033.